Other News To Note

• BioAlliance Pharma SA, of Paris, said more than 30 percent of its planned patients have been enrolled in the Phase II trial testing clonidine Lauriad and, to date, there have been no reports of any particular toxicity related to the product. BioAlliance now is planning to enlarge the trial to accelerate recruitment, which should be finalized in 2013. Clonidine Lauriad is in development for treating oral mucositis.